In vivo assessment of the combination of the JAK1 selective inhibitor itacitinib with first- and second-generation EGFR inhibitors in models of non-small cell lung cancer

被引：2
|
作者：
Stubbs, Matthew C. [1 ]
Wen, Xiaoming [1 ]
Xue, Chu-Biao [1 ]
Huang, Taisheng [1 ]
Yao, Wenqing [1 ]
Metcalf, Brian [1 ]
Huber, Reid [1 ]
Scherle, Peggy [1 ]
Ruggeri, Bruce [1 ]
机构：
[1] Incyte Corp, Wilmington, DE USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2938
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2938
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preventing Symptomatic Central Nervous System Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Comparison of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors
    Zhou, Y.
    Ni, J.
    Zhu, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E751 - E751
  • [32] A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors
    Mitsuya, S.
    Tsuruoka, K.
    Kanaoka, K.
    Funamoto, T.
    Tsuji, H.
    Matsunaga, N.
    Nakamura, T.
    Tamura, Y.
    Imanishi, M.
    Ikeda, S.
    Fujisaka, Y.
    Goto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S596 - S596
  • [33] Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
    Ma, Jietao
    Huang, Letian
    Han, Chengbo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [34] Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma
    Tripathi, Surya Kant
    Biswal, Bijesh K.
    DRUG DISCOVERY TODAY, 2021, 26 (06) : 1466 - 1472
  • [35] Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
    Dal Maso, A.
    Ferro, A.
    Lorenzi, M.
    Polo, V.
    Scattolin, D.
    Del Conte, A.
    Scoccia, E.
    Frega, S.
    Bonanno, L.
    Indraccolo, S.
    Calabrese, F.
    Guarneri, V.
    Conte, P. F.
    Pasello, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S886
  • [36] Comparison of the efficacy of first-/second-generation EGFR-tyrosine kinase inhibitors and osimertinib for EGFR-mutant lung cancer with negative or low PD-L1 expression
    Inomata, Minehiko
    Minatoyama, Shuhei
    Takata, Naoki
    Hayashi, Kana
    Hirai, Takahiro
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Tobe, Kazuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 20 (06)
  • [37] First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Yang, Chih-Hsin
    Wu, Shang-Gin
    Chiu, Yueh-Hsia
    Gow, Chien-Hung
    Chang, Yeun-Chung
    Hsu, Ya-Chieh
    Wei, Pin-Fei
    Shih, Jin-Yuan
    Yang, Pan-Chyr
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) : 847 - 853
  • [38] Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Wang, Mengzhao
    Yang, James Chih-Hsin
    Mitchell, Paul L.
    Fang, Jian
    Camidge, D. Ross
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Yang, Tsung-Ying
    Zhu, Viola W.
    Millward, Michael
    Fan, Yun
    Huang, Wen-Tsung
    Cheng, Ying
    Jiang, Liyan
    Brungs, Daniel
    Bazhenova, Lyudmila
    Lee, Chee Khoon
    Gao, Bo
    Xu, Yan
    Hsu, Wei-Hsun
    Zheng, Li
    Janne, Pasi A.
    CANCER DISCOVERY, 2022, 12 (07) : 1676 - 1689
  • [39] Real-World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation Treated with First and Second Generation TKI
    Juarez, D.
    Ruiz, R.
    Gutierrez, J. M.
    Mas, L.
    Morante, Z.
    Aguilar, A.
    Flores, C.
    Paytan, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S600 - S600
  • [40] Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells
    Elsocht, Mathias
    Giron, Philippe
    De Greve, Jacques
    Ballet, Steven
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79
12345